TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Linking Microcredit, Technology, and Promotion of IYCF Breastfeeding Guidelines in Bauchi State, Nigeria
Brief Summary: The University of North Carolina (UNC) and Partners for Development (PFD), an American non-governmental organization, will conduct a 2-year cluster-randomized controlled trial in Bauchi State, Nigeria, to test the effectiveness of two behavior change strategies for increasing the proportion of participants who exclusively breastfeed their infants until 6 months. The investigators will build upon PFD's existing microcredit and reproductive health program by adding face-to-face breastfeeding education during borrowers' meetings and bi-weekly cell phone breastfeeding messages. The hypothesis is that the control group will remain at the baseline level for exclusive breastfeeding to 6 months, while the intervention group will increase by 15%. The investigators will measure the effectiveness of the intervention by conducting baseline and final surveys with a cohort of 485 female borrowers who are pregnant at time 1 and who have a 6-month-old infant at time 2. The data will be analyzed using logistic regression adjusting for possible confounders and the effect of clustering.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Community Health Workers; Type: EXPERIMENTAL; Interventions: Behavioral: community health workers | Intervention Type: BEHAVIORAL; Name: community health workers; Assigned to Arm(s): Community Health Workers
B: Arm Label: EMONC: Community mobilization, HBLSS and Facility Improvement; Type: EXPERIMENTAL; Interventions: Behavioral: Community Mobilization, HBLSS and facility improvement | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Community Mobilization, HBLSS and facility improvement; Assigned to Arm(s): EMONC: Community mobilization, HBLSS and Facility Improvement
C: Intervention Type: DRUG; Name: Co-Trimoxazole; TMP-SMZ; Assigned to Arm(s): N/A
D: Arm Label: Breastfeeding promotion intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Breastfeeding promotion intervention | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding promotion intervention; Assigned to Arm(s): Breastfeeding promotion intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Linking Microcredit, Technology, and Promotion of IYCF Breastfeeding Guidelines in Bauchi State, Nigeria
Brief Summary: The University of North Carolina (UNC) and Partners for Development (PFD), an American non-governmental organization, will conduct a 2-year cluster-randomized controlled trial in Bauchi State, Nigeria, to test the effectiveness of two behavior change strategies for increasing the proportion of participants who exclusively breastfeed their infants until 6 months. The investigators will build upon PFD's existing microcredit and reproductive health program by adding face-to-face breastfeeding education during borrowers' meetings and bi-weekly cell phone breastfeeding messages. The hypothesis is that the control group will remain at the baseline level for exclusive breastfeeding to 6 months, while the intervention group will increase by 15%. The investigators will measure the effectiveness of the intervention by conducting baseline and final surveys with a cohort of 485 female borrowers who are pregnant at time 1 and who have a 6-month-old infant at time 2. The data will be analyzed using logistic regression adjusting for possible confounders and the effect of clustering.


Options:
A: Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Behavioral education; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral education intervention | Intervention Type: BEHAVIORAL; Name: Behavioral education intervention; Assigned to Arm(s): Behavioral education
B: Arm Label: Breastfeeding promotion intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Breastfeeding promotion intervention | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Breastfeeding promotion intervention; Assigned to Arm(s): Breastfeeding promotion intervention
C: Arm Label: advisory support; Type: EXPERIMENTAL; Interventions: Behavioral: advisory support | Intervention Type: BEHAVIORAL; Name: advisory support; Assigned to Arm(s): advisory support
D: Intervention Type: BEHAVIORAL; Name: Lactation counseling; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Enhancing Exposure Therapy for PTSD: Virtual Reality and Imaginal Exposure With a Cognitive Enhancer
Brief Summary: The purpose of this study is to test the differences between four active treatment conditions for combat-related Post Traumatic Stress Disorder (PTSD): virtual reality exposure therapy (VRE) or prolonged imaginal exposure therapy (PE), both with DCS or placebo, as well as to examine predictors for PTSD and response to treatment in active duty military personnel, veterans, and civilians who served in Iraq and Afghanistan.


Options:
A: Arm Label: D-cycloserine plus CBT; Type: ACTIVE_COMPARATOR; Interventions: Drug: D-cycloserine, Behavioral: CBT | Arm Label: Placebo pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo pill, Behavioral: CBT | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): D-cycloserine plus CBT | Intervention Type: DRUG; Name: Placebo pill; Assigned to Arm(s): Placebo pill | Intervention Type: BEHAVIORAL; Name: CBT; Assigned to Arm(s): D-cycloserine plus CBT, Placebo pill
B: Arm Label: Sugar Pill; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Individual Cognitive Behavioral Therapy (CBT), Drug: Placebo | Arm Label: D-Cycloserine; Type: EXPERIMENTAL; Interventions: Behavioral: Individual Cognitive Behavioral Therapy (CBT), Drug: D-Cycloserine | Intervention Type: BEHAVIORAL; Name: Individual Cognitive Behavioral Therapy (CBT); Assigned to Arm(s): D-Cycloserine, Sugar Pill | Intervention Type: DRUG; Name: D-Cycloserine; Assigned to Arm(s): D-Cycloserine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sugar Pill
C: Intervention Type: BEHAVIORAL; Name: Cognitive behavioral therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: D-cycloserine; Assigned to Arm(s): N/A
D: Arm Label: Placebo + Prolonged Imaginal Exposure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + Prolonged Imaginal Exposure | Arm Label: Placebo + VR exposure; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo (sugar pill) + Virtual Reality Exposure | Arm Label: DCS + Prolonged Imaginal Exposure; Type: ACTIVE_COMPARATOR; Interventions: Drug: DCS (D-Cycloserine ) + Prolonged Imaginal Exposure | Arm Label: DCS+VR exposure; Type: ACTIVE_COMPARATOR; Interventions: Drug: DCS (D-Cycloserine ) + Virtual Reality Exposure | Intervention Type: DRUG; Name: DCS (D-Cycloserine ) + Prolonged Imaginal Exposure; Assigned to Arm(s): DCS + Prolonged Imaginal Exposure | Intervention Type: DRUG; Name: DCS (D-Cycloserine ) + Virtual Reality Exposure; Assigned to Arm(s): DCS+VR exposure | Intervention Type: DRUG; Name: Placebo + Prolonged Imaginal Exposure; Assigned to Arm(s): Placebo + Prolonged Imaginal Exposure | Intervention Type: DRUG; Name: Placebo (sugar pill) + Virtual Reality Exposure; Assigned to Arm(s): Placebo + VR exposure

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of the Effect of Hydrocortisone on Survival Without Bronchopulmonary Dysplasia and on Neurodevelopmental Outcomes at 22 - 26 Months of Age in Intubated Infants < 30 Weeks Gestation Age
Brief Summary: The Hydrocortisone and Extubation study will test the safety and efficacy of a 10 day course of hydrocortisone for infants who are less than 30 weeks estimated gestational age and who are intubated at 14-28 days of life. Infants will be randomized to receive hydrocortisone or placebo. This study will determine if hydrocortisone improves infants'survival without moderate or severe BPD and will be associated with improvement in survival without moderate or severe neurodevelopmental impairment at 22 - 26 months corrected age.


Options:
A: Arm Label: 1: hydrocortisone; Type: EXPERIMENTAL; Interventions: Drug: hydrocortisone | Arm Label: 2: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: hydrocortisone; Assigned to Arm(s): 1: hydrocortisone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2: Placebo
B: Arm Label: Dopamine and hydrocortisone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dopamine, Drug: Hydrocortisone | Arm Label: Dopamine and placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dopamine, Drug: Syringe Placebo | Arm Label: Placebo and hydrocortisone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydrocortisone, Drug: Infusion Placebo | Arm Label: Placebo and Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Infusion Placebo, Drug: Syringe Placebo | Intervention Type: DRUG; Name: Dopamine; Assigned to Arm(s): Dopamine and hydrocortisone, Dopamine and placebo | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): Dopamine and hydrocortisone, Placebo and hydrocortisone | Intervention Type: DRUG; Name: Infusion Placebo; Assigned to Arm(s): Placebo and Placebo, Placebo and hydrocortisone | Intervention Type: DRUG; Name: Syringe Placebo; Assigned to Arm(s): Dopamine and placebo, Placebo and Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Hydrocortisone; Type: EXPERIMENTAL; Interventions: Drug: Hydrocortisone | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): Hydrocortisone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Hydrocortisone | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Metformin in Women With Type 2 Diabetes in Pregnancy Trial
Brief Summary: Insulin is the standard treatment for the management of type 2 diabetes in pregnancy, however despite treatment with insulin, these women continue to face increased rates of adverse maternal and fetal outcomes. The investigators hypothesize that metformin use, in addition to treatment with insulin, will help with blood sugar control, lower the dose of insulin needed, lower weight gain, and improve baby outcomes.


Options:
A: Arm Label: metformin; Type: EXPERIMENTAL; Interventions: Drug: Metformin | Arm Label: insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): metformin | Intervention Type: DRUG; Name: Insulin; Assigned to Arm(s): insulin
B: Arm Label: Glyburide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glyburide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Glyburide; Assigned to Arm(s): Glyburide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Comparator | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin | Intervention Type: DRUG; Name: Placebo Comparator; Assigned to Arm(s): Placebo
D: Arm Label: Nutritional counseling & self blood glucose monitoring; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: nutritional counseling, Behavioral: self blood glucose monitoring | Arm Label: No treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: nutritional counseling; Assigned to Arm(s): Nutritional counseling & self blood glucose monitoring | Intervention Type: BEHAVIORAL; Name: self blood glucose monitoring; Assigned to Arm(s): Nutritional counseling & self blood glucose monitoring

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Text Messaging Intervention to Improve ART Adherence Among HIV-positive Youth
Brief Summary: The purpose of the proposed study is to test SMS (short message service) text messaging technology to improve medication adherence among youth living with HIV (YLH). The proposed study is a randomized controlled trial of the effect of text message reminders on ART (anti-retroviral therapy) adherence among non-adherent YLH. Daily text message reminders will be sent to patients randomized to the intervention group according to their medication schedule, for 6 months. The investigators will enroll non-adherent YLH, ages 16-29. Half of the sample, randomized to the intervention, will receive daily SMS text message medication reminders and half will be randomized to the control condition and receive standard of care (SOC) only. For the controlled trial, adherence levels and viral load will be collected at baseline, 3-month and 6-month follow-up. In addition, at the end of the initial 6-month enrollment period, participants in the control condition will cross-over to the SMS intervention and participants in the intervention condition will cease to receive the SMS intervention. Adherence and viral load data will be collected from each group at 9- and 12-month follow-up points. The investigators hypothesize that youth in the intervention condition will demonstrate a clinically meaningful increase in adherence at 3 and 6 months post-baseline, from approximately 70% to 90% adherence to ART.


Options:
A: Arm Label: Standard of care only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: SMS Text Message Reminder | Intervention Type: BEHAVIORAL; Name: SMS Text Message Reminder; Assigned to Arm(s): Intervention
B: Arm Label: Telephone reminder; Type: EXPERIMENTAL; Interventions: Other: Telephone reminder | Arm Label: Text Message reminder; Type: EXPERIMENTAL; Interventions: Other: Text Message reminder | Arm Label: Control: Telephone; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Control: Text Message; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Telephone reminder; Assigned to Arm(s): Telephone reminder | Intervention Type: OTHER; Name: Text Message reminder; Assigned to Arm(s): Text Message reminder
C: Arm Label: Reminder module (SMS and Phone call); Type: EXPERIMENTAL; Interventions: Behavioral: Reminder module (SMS and Phone call) | Arm Label: Photovoice; Type: EXPERIMENTAL; Interventions: Behavioral: Photovoice | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Reminder module (SMS and Phone call); Assigned to Arm(s): Reminder module (SMS and Phone call) | Intervention Type: BEHAVIORAL; Name: Photovoice; Assigned to Arm(s): Photovoice
D: Arm Label: Connected to Care; Type: EXPERIMENTAL; Interventions: Behavioral: Connected to Care | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Connected to Care; Assigned to Arm(s): Connected to Care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Text Messaging Intervention to Improve ART Adherence Among HIV-positive Youth
Brief Summary: The purpose of the proposed study is to test SMS (short message service) text messaging technology to improve medication adherence among youth living with HIV (YLH). The proposed study is a randomized controlled trial of the effect of text message reminders on ART (anti-retroviral therapy) adherence among non-adherent YLH. Daily text message reminders will be sent to patients randomized to the intervention group according to their medication schedule, for 6 months. The investigators will enroll non-adherent YLH, ages 16-29. Half of the sample, randomized to the intervention, will receive daily SMS text message medication reminders and half will be randomized to the control condition and receive standard of care (SOC) only. For the controlled trial, adherence levels and viral load will be collected at baseline, 3-month and 6-month follow-up. In addition, at the end of the initial 6-month enrollment period, participants in the control condition will cross-over to the SMS intervention and participants in the intervention condition will cease to receive the SMS intervention. Adherence and viral load data will be collected from each group at 9- and 12-month follow-up points. The investigators hypothesize that youth in the intervention condition will demonstrate a clinically meaningful increase in adherence at 3 and 6 months post-baseline, from approximately 70% to 90% adherence to ART.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention (text); Type: EXPERIMENTAL; Interventions: Behavioral: SmokefreeMOM Text | Arm Label: Intervention Plus (text+quitline); Type: EXPERIMENTAL; Interventions: Behavioral: SmokefreeMOM Text | Intervention Type: BEHAVIORAL; Name: SmokefreeMOM Text; Assigned to Arm(s): Intervention (text), Intervention Plus (text+quitline)
B: N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Text messaging reminders | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Text messaging reminders; Assigned to Arm(s): 1
D: Arm Label: Standard of care only; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: SMS Text Message Reminder | Intervention Type: BEHAVIORAL; Name: SMS Text Message Reminder; Assigned to Arm(s): Intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Preoperative Feeding With a Whey Protein Plus Carbohydrate Drink on the Acute Phase Response and Insulin Resistance.
Brief Summary: Prolonged fasting may increase the organic response to trauma. Carbohydrate-based drinks have been tested and they may reduce insulin resistance. No study so far has aimed to examine the possible benefits of whey protein drink in the composition of preoperative drinks.


Options:
A: Arm Label: water; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: whey protein plus carbohydrate drink | Arm Label: whey protein plus carbohydrate; Type: EXPERIMENTAL; Interventions: Dietary Supplement: whey protein plus carbohydrate drink | Intervention Type: DIETARY_SUPPLEMENT; Name: whey protein plus carbohydrate drink; Assigned to Arm(s): water, whey protein plus carbohydrate
B: Arm Label: Aminolaban EN; Type: EXPERIMENTAL; Interventions: Drug: Aminoleban EN | Arm Label: Control; Type: NO_INTERVENTION; Interventions: Drug: Aminoleban EN | Intervention Type: DRUG; Name: Aminoleban EN; Assigned to Arm(s): Aminolaban EN, Control
C: Arm Label: CHO; Type: EXPERIMENTAL; Interventions: Dietary Supplement: PreOp carbohydrate drink | Arm Label: FAST; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: PreOp carbohydrate drink; Assigned to Arm(s): CHO
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard ERAS group | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Post operative laxation (Magnesium Oxide) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Preoperative metabolic conditioning postoperative nutritional supplementation | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Post operative laxation (Magnesium Oxide), Dietary Supplement: Preoperative metabolic conditioning postoperative nutritional supplementation | Intervention Type: DRUG; Name: Post operative laxation (Magnesium Oxide); Assigned to Arm(s): 2, 4 | Intervention Type: DIETARY_SUPPLEMENT; Name: Preoperative metabolic conditioning postoperative nutritional supplementation; Assigned to Arm(s): 3, 4 | Intervention Type: OTHER; Name: Standard ERAS group; Assigned to Arm(s): 1

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Blinded, Phase 2 Dose-Ranging Study Of BMS-936558 (MDX-1106) In Subjects With Progressive, Advanced/Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
Brief Summary: The purpose of this study is to measure how active BMS-936558 (nivolumab) is against Renal Cell Carcinoma (RCC) as measured by the disease not progressing and whether a dose response relationship exists.


Options:
A: Arm Label: Cohort A: MSI Positive Colorectal Cancer; Type: EXPERIMENTAL; Interventions: Drug: MK-3475 | Arm Label: Cohort B: MSI Negative Colorectal Cancer; Type: EXPERIMENTAL; Interventions: Drug: MK-3475 | Arm Label: Cohort C: MSI Positive Non-Colorectal Cancer; Type: EXPERIMENTAL; Interventions: Drug: MK-3475 | Intervention Type: DRUG; Name: MK-3475; Assigned to Arm(s): Cohort A: MSI Positive Colorectal Cancer, Cohort B: MSI Negative Colorectal Cancer, Cohort C: MSI Positive Non-Colorectal Cancer
B: Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Arm Label: IMA901 plus GM-CSF added to sunitinib after single dose of cy; Type: EXPERIMENTAL; Interventions: Drug: Sunitinib, Biological: GM-CSF, Drug: Cyclophosphamide, Drug: IMA901 | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): IMA901 plus GM-CSF added to sunitinib after single dose of cy, Sunitinib | Intervention Type: BIOLOGICAL; Name: GM-CSF; Assigned to Arm(s): IMA901 plus GM-CSF added to sunitinib after single dose of cy | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): IMA901 plus GM-CSF added to sunitinib after single dose of cy | Intervention Type: DRUG; Name: IMA901; Assigned to Arm(s): IMA901 plus GM-CSF added to sunitinib after single dose of cy
C: Arm Label: 1: AGS-003+sunitinib; Type: EXPERIMENTAL; Interventions: Biological: AGS-003, Drug: Sunitinib | Intervention Type: BIOLOGICAL; Name: AGS-003; Assigned to Arm(s): 1: AGS-003+sunitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): 1: AGS-003+sunitinib
D: Arm Label: Arm 1: nivolumab - 0.3 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: nivolumab | Arm Label: Arm 2: nivolumab - 2.0 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: nivolumab | Arm Label: Arm 3: nivolumab - 10.0 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: nivolumab | Intervention Type: BIOLOGICAL; Name: nivolumab; Assigned to Arm(s): Arm 1: nivolumab - 0.3 mg/kg | Intervention Type: BIOLOGICAL; Name: nivolumab; Assigned to Arm(s): Arm 2: nivolumab - 2.0 mg/kg | Intervention Type: BIOLOGICAL; Name: nivolumab; Assigned to Arm(s): Arm 3: nivolumab - 10.0 mg/kg

Answer: D